Rising Cases Of Premature Births Driving Growth In The Market Due To Increasing Risk In Preterm Infants: A Key Driver Powering Necrotizing Enterocolitis Market Growth In 2025

The Necrotizing Enterocolitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Necrotizing Enterocolitis Market Size and Its Estimated Growth Rate?
The market for necrotizing enterocolitis has seen a robust expansion in recent years. Projected to escalate from $4.83 billion in 2024 to $5.16 billion in 2025, it has a predicted compound annual growth rate (CAGR) of 6.8%. This substantial growth during the historical period can be traced back to several factors such as the growing instances of necrotizing enterocolitis, surging population size, rising per capita income, enhanced government funding, and an increase in premature birth occurrences.

Expectations are high for robust growth in the necrotizing enterocolitis market in the next several years. The market is projected to increase to $6.62 billion in 2029 with a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this upturn during the forecast period include increasing healthcare costs, the occurrence and commonality of ulcerative colitis (UC), the rise in gastrointestinal maladies, a growing number of aged and overweight individuals, and a burgeoning elderly demographic. Notable trends projected for the forecast period incorporate progress in biomarker research for early NEC detection, innovations in non-invasive test procedures, the incorporation of cutting-edge monitoring systems, advancements in surgical methodologies, and the creation of targeted therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

How Are Emerging Segments Shaping the Necrotizing Enterocolitis Market Landscape?
The necrotizing enterocolitis market covered in this report is segmented -

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments
2) By Diagnosis: Laboratory Tests, Imaging Techniques
3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)
4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:
1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid s In TPN, Micronutrient And Electrolyte-Enhanced TPN
2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques
3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates
4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC
5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques
6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Which Growth Factors Are Influencing Necrotizing Enterocolitis Market Expansion?
The rise in premature birth instances is anticipated to spur the expansion of the necrotizing enterocolitis market in the future. Premature or preterm births refer to when a baby is delivered before reaching 37 weeks of gestation, contrasting the standard 40-week pregnancy period. The escalating occurrences of such births can be attributed to maternal health issues like high blood pressure, diabetes, infections that boost the probability of preterm labor. Moreover, lifestyle practices such as smoking, drug usage, and inadequate nutrition raise the chances of premature births. This surge in premature births leads to more instances of necrotizing enterocolitis (NEC) as preterm infants possess underdeveloped gastrointestinal systems, elevating their vulnerability to inflammation and infections. For example, the Centers for Disease Control and Prevention, a governmental agency in the US, reported in January 2024 that annually, premature births correspond to 8.67% of total births in the nation. Consequently, the mounting instances of premature births are stimulating the growth of the necrotizing enterocolitis market.

Who Are the Dominant Players Across Different Necrotizing Enterocolitis Market Segments?
Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

What Are the Latest Developing Trends in the Necrotizing Enterocolitis Market?
Leading companies in the necrotizing enterocolitis market are concentrating on creating innovative product solutions such as cell-free sterile biologic solutions to meet the significant unaddressed demand for effective treatments and better outcomes for premature babies. A cell-free sterile biologic solution is a refined, sterile liquid that consists of bioactive molecules like proteins, growth factors, and cytokines derived from harvested cells, yet not containing any intact cells. It is intended to enhance healing and lessen inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc., an American biopharmaceutical firm, got a green signal from the U.S. Food and Drug Administration (FDA) to continue with its Phase 1-2 clinical trial for ST266, an innovative biologic targeted at curing necrotizing enterocolitis (NEC) in premature infants. This represents a momentous milestone as ST266 is poised to be the first significant therapeutic breakthrough for NEC in over three decades, addressing an urgent healthcare need due to the disease's considerable morbidity and mortality rates among susceptible groups.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Geographic Regions Are Expected to Dominate the Necrotizing Enterocolitis Market in the Coming Years?
North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Necrotizing Enterocolitis Market?
2. What is the CAGR expected in the Necrotizing Enterocolitis Market?
3. What Are the Key Innovations Transforming the Necrotizing Enterocolitis Industry?
4. Which Region Is Leading the Necrotizing Enterocolitis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.